450 related articles for article (PubMed ID: 1320544)
1. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
Zietse R; Wenting GJ; Kramer P; Schalekamp MA; Weimar W
Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
[TBL] [Abstract][Full Text] [Related]
2. [Effect of cyclosporin A on renal function in patients with glomerulonephritis].
Heering P; Schneider A; Grabensee B; Plum J
Dtsch Med Wochenschr; 2001 Oct; 126(40):1093-8. PubMed ID: 11588659
[TBL] [Abstract][Full Text] [Related]
3. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
[TBL] [Abstract][Full Text] [Related]
4. Contrasting response to cyclosporin in refractory nephrotic syndrome.
Zietse R; Wenting GJ; Kramer P; Mulder P; Schalekamp MA; Weimar W
Clin Nephrol; 1989 Jan; 31(1):22-5. PubMed ID: 2914407
[TBL] [Abstract][Full Text] [Related]
5. Treatment of the nephrotic syndrome with cyclosporin A.
Ponticelli C
J Autoimmun; 1992 Apr; 5 Suppl A():315-24. PubMed ID: 1503627
[TBL] [Abstract][Full Text] [Related]
6. Short-term responsiveness of membranous glomerulopathy to cyclosporine.
Guasch A; Suranyi M; Newton L; Hall BM; Myers BD
Am J Kidney Dis; 1992 Nov; 20(5):472-81. PubMed ID: 1442759
[TBL] [Abstract][Full Text] [Related]
7. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).
Yokoyama H; Sugiyama H; Narita I; Saito T; Yamagata K; Nishio S; Fujimoto S; Mori N; Yuzawa Y; Okuda S; Maruyama S; Sato H; Ueda Y; Makino H; Matsuo S
Clin Exp Nephrol; 2015 Jun; 19(3):496-505. PubMed ID: 25230687
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
[TBL] [Abstract][Full Text] [Related]
10. [Indications for cyclosporin in the treatment of idiopathic nephrotic syndrome in adults].
Zietse R; Weimar W
Ned Tijdschr Geneeskd; 1992 Sep; 136(36):1749-53. PubMed ID: 1407123
[No Abstract] [Full Text] [Related]
11. Cyclosporin A in the treatment of patients with nephrotic syndrome.
Pandeva SM; Tzekov VD; Kumchev EP; Tilkian EE; Nikolov DG; Tzvetkova ZT; Manev EI; Anavi BL; Dimitrakov DJ
Folia Med (Plovdiv); 2000; 42(2):38-41. PubMed ID: 11217282
[TBL] [Abstract][Full Text] [Related]
12. Characterization of proteinuria in primary glomerulonephritides: urinary polymers of albumin.
Bazzi C; Petrini C; Rizza V; Arrigo G; Beltrame A; D'Amico G
Am J Kidney Dis; 1997 Sep; 30(3):404-12. PubMed ID: 9292570
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine in idiopathic nephrotic syndrome.
Ponticelli C
Immunopharmacol Immunotoxicol; 1993 Aug; 15(4):479-89. PubMed ID: 8227973
[TBL] [Abstract][Full Text] [Related]
14. Extent and course of glomerular injury in human membranous glomerulopathy.
Guasch A; Sibley RK; Huie P; Myers BD
Am J Physiol; 1992 Dec; 263(6 Pt 2):F1034-43. PubMed ID: 1282782
[TBL] [Abstract][Full Text] [Related]
15. Enalapril can treat the proteinuria of membranous glomerulonephritis without detriment to systemic or renal hemodynamics.
Thomas DM; Hillis AN; Coles GA; Davies M; Williams JD
Am J Kidney Dis; 1991 Jul; 18(1):38-43. PubMed ID: 1712151
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy.
Zietse R; Derkx FH; Schalekamp MA; Weimar W
Contrib Nephrol; 1995; 114():6-18. PubMed ID: 7587200
[No Abstract] [Full Text] [Related]
17. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy.
Morelli E; Loon N; Meyer T; Peters W; Myers BD
Diabetes; 1990 Jan; 39(1):76-82. PubMed ID: 1698674
[TBL] [Abstract][Full Text] [Related]
18. Nature of the glomerular capillary injury in human membranous glomerulopathy.
Shemesh O; Ross JC; Deen WM; Grant GW; Myers BD
J Clin Invest; 1986 Mar; 77(3):868-77. PubMed ID: 2419362
[TBL] [Abstract][Full Text] [Related]
19. Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment.
Hommos MS; Zeng C; Liu Z; Troost JP; Rosenberg AZ; Palmer M; Kremers WK; Cornell LD; Fervenza FC; Barisoni L; Rule AD
Kidney Int; 2018 May; 93(5):1175-1182. PubMed ID: 29273332
[TBL] [Abstract][Full Text] [Related]
20. The racial prevalence of glomerular lesions in nephrotic adults.
Korbet SM; Genchi RM; Borok RZ; Schwartz MM
Am J Kidney Dis; 1996 May; 27(5):647-51. PubMed ID: 8629623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
